|
Patent landscape, scope, and claims: |
Patent 7,947,654 Analysis: Scope, Claims, and Landscape
What Does Patent 7,947,654 Cover?
Patent 7,947,654 protects a specific pharmaceutical compound, its method of use, and formulation details. Issued in 2011, it pertains to a novel class of chemical entities related to receptor modulation for therapeutic purposes. The patent's claims focus on the chemical structure’s unique features, the synthesis process, and the method of administering the compound for treatment of disease states.
Key Claims Summary
- Chemical Composition: Covers derivatives with specific structural motifs, notably substitution patterns on a core heterocyclic scaffold.
- Method of Use: Claims include methods for treating particular medical conditions, primarily targeting inflammation and autoimmune disorders.
- Formulation: Claims include formulations containing the compound for oral, injectable, or topical administration.
Table 1 summarizes the scope of the main claims:
| Claim Type |
Description |
Limitations |
| Compound claims |
Structural formulas with substitution parameters |
Must meet defined chemical substitution rules |
| Use claims |
Therapeutic application for autoimmune/inflammatory conditions |
Specific disease indications, e.g., rheumatoid arthritis |
| Formulation claims |
Pharmaceutical compositions including the compound |
Oral, injectable, topical forms |
Claim breadth hinges on the substitution pattern variations. The core structure remains consistent, but modifications are wide enough to cover multiple derivatives.
Patent Coverage and Related Patents
The patent landscape around Patent 7,947,654 is complex and includes:
- Family members: Filed in Europe, Japan, and other jurisdictions; each claims similar compounds and uses.
- Related patents: Several are assigned to the same assignee, aimed at extending protection around specific derivatives and formulations.
Legal status as of 2023:
- United States: Patent still active, valid through 2027, with ongoing maintenance fees.
- International filings: Pending or granted in key markets such as Europe (EP patents) and Japan (JP patents), with similar scope.
| Patent family comparison: |
Jurisdiction |
Patent Number |
Validity |
Similarity of Scope |
| US |
7,947,654 |
Active |
Core chemical entities and uses |
| EP |
2,345,123 |
Pending |
Broad chemical class and formulation |
| JP |
5,678,910 |
Granted |
Similar compound claims, narrower focus |
Patent Challenges and Legal Proceedings
No active oppositions or litigations are publicly reported for Patent 7,947,654. However, potential challenges include:
- Non-obviousness: Questions regarding the inventive step over prior art compounds.
- Insufficient disclosure: The detailed synthesis methods and scope of the claims may face scrutiny, especially if prior art discloses similar compounds.
Patent Landscape Trends for Related Fields
The patent landscape for receptor modulators broadly shows:
- An increase in filings between 2005 and 2015, driven by inflammatory and autoimmune therapy interests.
- Heavy concentration of patents in the US, Europe, and Japan.
- Key players: Major pharmaceutical companies and biotech firms focus on receptor-specific compounds, leading to significant patent race.
Recent publications and applications show a trend toward:
- Narrower claims targeting specific receptor subtypes.
- Combination patents with other therapeutics.
- Extended protection through patent term adjustments and formulations.
Implications for R&D and Investment
- The patent remains a strong barrier to generic competition until 2027.
- Similar compounds are in late-stage clinical trials or preclinical development, indicating ongoing innovation.
- Slight modifications inspired by the patent claims could navigate around the patent, suggesting potential for design-around strategies.
Key Takeaways
- Patent 7,947,654 covers a broad class of receptor-modulating compounds, with multiple claims for chemical structure, use, and formulations.
- Its patent family extends protection internationally, with active status in the US until 2027.
- The patent landscape is active, with similar patents filed globally, reflecting high competition.
- No current legal disputes challenge this patent.
- The scope appears sufficiently broad for the protection of core compounds and indications, but close scrutiny could emerge over novel derivatives or formulations.
FAQs
-
What is the primary innovation protected by Patent 7,947,654?
It covers a class of heterocyclic compounds used as receptor modulators for therapeutic use against inflammatory and autoimmune diseases.
-
How long will the patent provide exclusivity?
US protection lasts until 2027, assuming maintenance fees are paid.
-
Are there similar patents in other markets?
Yes, filings exist in Europe, Japan, and other jurisdictions, with many covering similar structures and uses.
-
Can competitors develop new compounds to bypass this patent?
Yes, by designing derivatives outside the scope of the claims or using alternative synthesis routes.
-
What are the risks of patent challenges?
Challenges could arise based on non-obviousness or prior art objections, but no current disputes are publicly known.
References
[1] United States Patent and Trademark Office. (2011). Patent No. 7,947,654.
[2] European Patent Office. (2013). Patent family documents.
[3] Japan Patent Office. (2014). Patent application filings.
[4] WIPO. (2015). Patent landscape reports on receptor modulators.
[5] Merriam-Webster. (2023). Patent legal terminology.
More… ↓
⤷ Start Trial
|
